Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration

Karen Bjerg Pedersen, Flemming Møller, Anne Katrin Sjølie, Sten Andréasson

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

PURPOSE: The purpose of this study was to assess the alteration of retinal function by multifocal electroretinography and full-field electroretinography in patients with age-related macular degeneration treated with bevacizumab.

METHODS: We performed a prospective pilot study of 26 eyes of 26 previously treatment-naïve patients with neovascular age-related macular degeneration receiving intravitreal injections with 1.25 mg bevacizumab. Patients were examined with multifocal electroretinography, full-field electroretinography, optical coherence tomography, and visual acuity. Follow-up was performed at 1 week, 6 weeks, 3 months, and 6 months.

RESULTS: Mean multifocal electroretinography P1 amplitudes were significantly improved at 1 week in the central zone and after 3 and 6 months, improvement was seen in all 6 concentric rings corresponding to +/-25 degrees of the central visual field. Full-field electroretinography results indicated a decrease in cone photoreceptor function at 3 months, which was normalized at 6 months compared with baseline. Furthermore, 2 of 3 of the combined rod-cone responses showed signs of decreased retinal function at 6 months.

CONCLUSION: Our results indicate passing signs of an altered retinal cone photoreceptor function assessed by full-field electroretinography. The results do not show any conclusive signs of global retinal toxicity after 6 months. Multifocal electroretinography results show improved photoreceptor function with no sign of focal toxicity in the central retina.

OriginalsprogEngelsk
TidsskriftRetina
Vol/bind30
Udgave nummer7
Sider (fra-til)1025-33
Antal sider9
ISSN0275-004X
DOI
StatusUdgivet - 10. jul. 2010

Fingeraftryk

Electroretinography
Macular Degeneration
Retinal Cone Photoreceptor Cells
Vertebrate Photoreceptor Cells
Bevacizumab
Optical Coherence Tomography
Visual Fields
Visual Acuity
Retina
Prospective Studies

Citer dette

@article{cdc99c67ada14bae9cee18225d51f879,
title = "Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration",
abstract = "PURPOSE: The purpose of this study was to assess the alteration of retinal function by multifocal electroretinography and full-field electroretinography in patients with age-related macular degeneration treated with bevacizumab.METHODS: We performed a prospective pilot study of 26 eyes of 26 previously treatment-na{\"i}ve patients with neovascular age-related macular degeneration receiving intravitreal injections with 1.25 mg bevacizumab. Patients were examined with multifocal electroretinography, full-field electroretinography, optical coherence tomography, and visual acuity. Follow-up was performed at 1 week, 6 weeks, 3 months, and 6 months.RESULTS: Mean multifocal electroretinography P1 amplitudes were significantly improved at 1 week in the central zone and after 3 and 6 months, improvement was seen in all 6 concentric rings corresponding to +/-25 degrees of the central visual field. Full-field electroretinography results indicated a decrease in cone photoreceptor function at 3 months, which was normalized at 6 months compared with baseline. Furthermore, 2 of 3 of the combined rod-cone responses showed signs of decreased retinal function at 6 months.CONCLUSION: Our results indicate passing signs of an altered retinal cone photoreceptor function assessed by full-field electroretinography. The results do not show any conclusive signs of global retinal toxicity after 6 months. Multifocal electroretinography results show improved photoreceptor function with no sign of focal toxicity in the central retina.",
keywords = "Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Choroidal Neovascularization, Electrophysiology, Electroretinography, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Pilot Projects, Prospective Studies, Retina, Tomography, Optical Coherence, Vascular Endothelial Growth Factor A, Visual Acuity, Vitreous Body",
author = "Pedersen, {Karen Bjerg} and Flemming M{\o}ller and Sj{\o}lie, {Anne Katrin} and Sten Andr{\'e}asson",
year = "2010",
month = "7",
day = "10",
doi = "10.1097/IAE.0b013e3181cafc8f",
language = "English",
volume = "30",
pages = "1025--33",
journal = "Retina",
issn = "0275-004X",
publisher = "Lippincott Williams & Wilkins",
number = "7",

}

Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration. / Pedersen, Karen Bjerg; Møller, Flemming; Sjølie, Anne Katrin; Andréasson, Sten.

I: Retina, Bind 30, Nr. 7, 10.07.2010, s. 1025-33.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Electrophysiological assessment of retinal function during 6 months of bevacizumab treatment in neovascular age-related macular degeneration

AU - Pedersen, Karen Bjerg

AU - Møller, Flemming

AU - Sjølie, Anne Katrin

AU - Andréasson, Sten

PY - 2010/7/10

Y1 - 2010/7/10

N2 - PURPOSE: The purpose of this study was to assess the alteration of retinal function by multifocal electroretinography and full-field electroretinography in patients with age-related macular degeneration treated with bevacizumab.METHODS: We performed a prospective pilot study of 26 eyes of 26 previously treatment-naïve patients with neovascular age-related macular degeneration receiving intravitreal injections with 1.25 mg bevacizumab. Patients were examined with multifocal electroretinography, full-field electroretinography, optical coherence tomography, and visual acuity. Follow-up was performed at 1 week, 6 weeks, 3 months, and 6 months.RESULTS: Mean multifocal electroretinography P1 amplitudes were significantly improved at 1 week in the central zone and after 3 and 6 months, improvement was seen in all 6 concentric rings corresponding to +/-25 degrees of the central visual field. Full-field electroretinography results indicated a decrease in cone photoreceptor function at 3 months, which was normalized at 6 months compared with baseline. Furthermore, 2 of 3 of the combined rod-cone responses showed signs of decreased retinal function at 6 months.CONCLUSION: Our results indicate passing signs of an altered retinal cone photoreceptor function assessed by full-field electroretinography. The results do not show any conclusive signs of global retinal toxicity after 6 months. Multifocal electroretinography results show improved photoreceptor function with no sign of focal toxicity in the central retina.

AB - PURPOSE: The purpose of this study was to assess the alteration of retinal function by multifocal electroretinography and full-field electroretinography in patients with age-related macular degeneration treated with bevacizumab.METHODS: We performed a prospective pilot study of 26 eyes of 26 previously treatment-naïve patients with neovascular age-related macular degeneration receiving intravitreal injections with 1.25 mg bevacizumab. Patients were examined with multifocal electroretinography, full-field electroretinography, optical coherence tomography, and visual acuity. Follow-up was performed at 1 week, 6 weeks, 3 months, and 6 months.RESULTS: Mean multifocal electroretinography P1 amplitudes were significantly improved at 1 week in the central zone and after 3 and 6 months, improvement was seen in all 6 concentric rings corresponding to +/-25 degrees of the central visual field. Full-field electroretinography results indicated a decrease in cone photoreceptor function at 3 months, which was normalized at 6 months compared with baseline. Furthermore, 2 of 3 of the combined rod-cone responses showed signs of decreased retinal function at 6 months.CONCLUSION: Our results indicate passing signs of an altered retinal cone photoreceptor function assessed by full-field electroretinography. The results do not show any conclusive signs of global retinal toxicity after 6 months. Multifocal electroretinography results show improved photoreceptor function with no sign of focal toxicity in the central retina.

KW - Aged

KW - Aged, 80 and over

KW - Angiogenesis Inhibitors

KW - Antibodies, Monoclonal

KW - Antibodies, Monoclonal, Humanized

KW - Choroidal Neovascularization

KW - Electrophysiology

KW - Electroretinography

KW - Female

KW - Humans

KW - Injections

KW - Macular Degeneration

KW - Male

KW - Middle Aged

KW - Pilot Projects

KW - Prospective Studies

KW - Retina

KW - Tomography, Optical Coherence

KW - Vascular Endothelial Growth Factor A

KW - Visual Acuity

KW - Vitreous Body

U2 - 10.1097/IAE.0b013e3181cafc8f

DO - 10.1097/IAE.0b013e3181cafc8f

M3 - Journal article

VL - 30

SP - 1025

EP - 1033

JO - Retina

JF - Retina

SN - 0275-004X

IS - 7

ER -